Boston Scientific Corporation(BSX)NASDAQ
Stock Overview & Analysis
Boston Scientific Corporation (BSX) quick overview 2026-02-20
- The stock is currently trading at $74.58, experiencing a short-term pullback within a declining trend—trading below its 50-day average while below the 200-day.
- Analysts appear optimistic, with a 1-year price target of $104.75 (40.5% upside).
- Volatility is elevated (54.14% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (15.90% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Boston Scientific Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $123.44B
P/E Ratio
Forward P/E: 19.42
Revenue Growth
Year over Year
Analyst Target
+40.5% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Oversold (RSI 28.10)
- Fundamentals say: Caution warranted (high leverage concerns)
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $11.97B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
Trading Range
Over the past year, the stock traded between $72.69 and $109.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 54.14% annualized volatility and β=0.66, the stock exhibits low sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.
Back on the Radar: Prior Picks Offer Fresh Opportunity
Periods of volatility often create the most compelling opportunities to revisit prior ideas with fresh perspective. This week I focus on opportunities within communication services, healthcare, and consumer staples. Netflix was covered by George Glover last December.
How Investors May Respond To Boston Scientific (BSX) EP Momentum And CHAMPION‑AF Data Overhang
Boston Scientific recently reported fourth-quarter 2025 sales of US$5,286 million and net income of US$672 million, alongside 2026 guidance calling for double‑digit reported and organic net sales growth. At the same time, the company is facing heightened attention on its electrophysiology and atrial fibrillation portfolio, with new clinical trials such as OPTION‑EMEA and upcoming CHAMPION‑AF data potentially influencing how investors view its long-term growth mix. We’ll now explore how...
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
JNJ's MedTech unit grows in 2025 on cardiovascular strength; with new launches, can 2026 bring faster growth?
3 S&P 500 Stocks Worth Investigating
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.
Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to invest in. On February 6, RBC Capital lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $115 from $130 and maintained an Outperform rating on the shares. RBC made the move in response to Boston Scientific’s Q4 2025 earnings share on […]
Boston Scientific Stock Slide Tests Support As Outlook And Value Diverge
Boston Scientific (NYSE: BSX) shares have fallen sharply in recent weeks, taking the stock back to technical support levels not seen for over a year. The pullback has coincided with reported institutional selling, even as the company reports solid operating performance. Management has expressed confidence in continuing to grow faster than the broader market, highlighting a gap between investor sentiment and the company outlook. For you as an investor, the tension between price action and...
Reassessing Boston Scientific (BSX) After A 30% Pullback In The Share Price
If you are wondering whether Boston Scientific is attractively priced or looking stretched at around US$74.73 per share, you are not alone. Many investors are reassessing what they are really paying for here. The stock recently closed at US$74.73, with returns of a 2.0% decline over 7 days, 20.3% decline over 30 days, 21.1% decline year to date, and 29.6% decline over 1 year, set against gains of 60.6% over 3 years and 96.5% over 5 years. Recent news has focused on Boston Scientific's...
Boston Scientific (BSX) Valuation After Mixed Q4 2025 Results And 2026 Growth Outlook
Boston Scientific (BSX) is in focus after reporting Q4 2025 and full year results that combined higher sales and earnings with mixed signals in key growth areas and guidance for 2026. See our latest analysis for Boston Scientific. The share price has retreated sharply in recent months, with a 30 day share price return of 20.28% and a 90 day return of 27.23%. However, the 3 year total shareholder return of 60.57% and 5 year total shareholder return of 96.50% remain well above these short term...
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $74.58. The RSI (14-day) is at 28.1, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $104.75 implies 40.5% upside from current levels. Volatility is high at 54.1% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 39.22, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.42, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.83, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.66. Price-to-Sales is 5.62. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 32 analysts covering BSX, the consensus price target is $104.75. This represents a 40.5% upside from the current price of $74.58. The range spans from a low target of $83.00 to a high target of $124.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. High volatility (54.1% annualized)—the stock can experience significant daily price swings. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $11.97B. The debt-to-equity ratio is 48.92, which is moderate and generally manageable for most companies. The current ratio is 1.62, indicating strong short-term liquidity. The quick ratio is 0.90. The company holds $1.96B in cash and equivalents. Free cash flow is positive at $3.24B, providing a cushion for debt servicing and shareholder returns.